Top Markets
#1 Orochi Network Orochi Network +75.87%
#2 Bitway Bitway +26.98%
#3 Audiera Audiera +26.10%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.60%
#5 Pharos Pharos +15.97%
#6 SOON SOON +15.22%
#7 DeXe DeXe +14.77%
#8 Taiko Taiko +13.85%
#9 Manadia Manadia +13.47%
#10 Cheems Token Cheems Token +13.12%
Coin of the day
Orochi Network Orochi Network
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Peringkat dalam Saham #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Harga Saham
$50.95
Kapitalisasi Pasar
$226.41B
Perubahan (1 hari)
2.58%
Perubahan (1 tahun)
-26.16%
Negara
DK
Perdagangan Novo Nordisk A/S (NVO)

Kategori

Healthcare
Laba untuk Novo Nordisk A/S (NVO)
Laba pada Mar 2026 TTM: $24.72B
Menurut laporan keuangan terbaru dari Novo Nordisk A/S, laba saat ini perusahaan adalah $24.72B. Pada tahun 2024, perusahaan memperoleh laba sebesar $17.75B, peningkatan dibandingkan laba tahun 2023 sebesar $15.50B. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Novo Nordisk A/S dari 2000 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $24.72B 25.36%
2025 $19.72B 11.11%
2024 $17.75B 14.50%
2023 $15.50B 55.92%
2022 $9.94B 10.02%
2021 $9.03B 3.59%
2020 $8.72B 19.69%
2019 $7.29B -0.35%
2018 $7.31B -6.79%
2017 $7.84B 15.64%
2016 $6.78B 7.06%
2015 $6.34B 14.26%
2014 $5.55B -7.59%
2013 $6.00B 22.00%
2012 $4.92B 28.80%
2011 $3.82B 16.43%
2010 $3.28B 21.42%
2009 $2.70B 13.54%
2008 $2.38B 10.14%
2007 $2.16B 33.54%
2006 $1.62B 24.30%
2005 $1.30B -5.19%
2004 $1.37B 6.85%
2003 $1.28B 44.62%
2002 $888.11M 23.73%
2001 $717.79M 18.82%
2000 $604.10M 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -79.10%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -79.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -91.35%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.48B -94.01%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
$586.40M -97.63%
US